Equities analysts predict that Kura Oncology Inc (NASDAQ:KURA) will post earnings of ($0.46) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Kura Oncology’s earnings. The highest EPS estimate is ($0.42) and the lowest is ($0.50). Kura Oncology posted earnings per share of ($0.36) in the same quarter last year, which would suggest a negative year-over-year growth rate of 27.8%. The company is expected to report its next quarterly earnings report on Wednesday, May 10th.
On average, analysts expect that Kura Oncology will report full-year earnings of ($2.31) per share for the current year, with EPS estimates ranging from ($2.91) to ($1.70). For the next year, analysts anticipate that the firm will report earnings of ($4.04) per share, with EPS estimates ranging from ($6.17) to ($1.91). Zacks’ EPS calculations are an average based on a survey of research firms that follow Kura Oncology.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, March 14th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03.
KURA has been the topic of several analyst reports. Cann reaffirmed an “outperform” rating and set a $18.00 target price on shares of Kura Oncology in a report on Monday, March 6th. Oppenheimer Holdings Inc. set a $18.00 price objective on Kura Oncology and gave the company a “buy” rating in a report on Monday, March 6th. Finally, Zacks Investment Research lowered Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, January 4th.
A number of hedge funds have recently modified their holdings of KURA. First Republic Investment Management Inc. acquired a new stake in shares of Kura Oncology during the fourth quarter valued at approximately $174,000. Renaissance Technologies LLC raised its stake in shares of Kura Oncology by 25.4% in the fourth quarter. Renaissance Technologies LLC now owns 30,600 shares of the company’s stock valued at $181,000 after buying an additional 6,200 shares during the last quarter. Finally, Partner Investment Management L.P. raised its stake in shares of Kura Oncology by 2.7% in the third quarter. Partner Investment Management L.P. now owns 23,646 shares of the company’s stock valued at $148,000 after buying an additional 623 shares during the last quarter. 45.73% of the stock is currently owned by institutional investors.
Shares of Kura Oncology (NASDAQ:KURA) traded up 0.97% on Thursday, reaching $10.40. 55,964 shares of the company’s stock were exchanged. The firm’s market cap is $201.21 million. Kura Oncology has a one year low of $2.50 and a one year high of $10.89. The company has a 50 day moving average price of $9.14 and a 200 day moving average price of $6.65.
ILLEGAL ACTIVITY NOTICE: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://sportsperspectives.com/2017/05/20/0-46-eps-expected-for-kura-oncology-inc-kura-this-quarter-updated-updated-updated.html.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.